USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Piao, Songlin ^a   Liu, Yanlong ^b   Hu, Jing ^b   Guo, Fulin ^a   Ma, Jie ^a   Sun, Yao ^c   Zhang, Bin ^c  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; KI 67 ANTIGEN; PROTEINASE; UBIQUITIN SPECIFIC PROTEASE 22; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RECURRENCE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; PROGNOSIS; THIOLESTER HYDROLASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; YOUNG ADULT;

EID: 84864535704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042540     Document Type: Article

References (24)

1. Hoeller D, Dikic I, (2009) Targeting the ubiquitin system in cancer therapy. Nature 458: 438-444.
2. Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM, et al. (2006) The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns 6: 277-284.
3. Glinsky GV, (2006) Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 5: 1208-1216.
4. Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, et al. (2008) A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell 29: 92-101.
5. Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, et al. (2008) The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 29: 102-111.
6. Pijnappel WW, Timmers HT, (2008) Dubbing SAGA unveils new epigenetic crosstalk. Mol Cell 29: 152-154.
7. Zhang XY, Pfeiffer HK, Thorne AW, McMahon SB, (2008) USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle 7: 1522-1524.
8. Liu YL, Yang YM, Xu H, Dong XS, (2011) Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol 103: 283-289.
9. Liu YL, Yang YM, Xu H, Dong XS, (2010) Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol 25: 1800-1805.
10. Zhang Y, Yao L, Zhang X, Ji H, Wang L, et al. (2011) Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol 137: 1245-1253.
11. Lv L, Xiao XY, Gu ZH, Zeng FQ, Huang LQ, et al. (2011) Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem 346: 11-21.
12. Lv T, Yuan D, Miao X, Lv Y, Zhan P, et al. (2012) Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One 7: e35065.
13. Liu YL, Jiang SX, Yang YM, Xu H, Liu JL, et al. (2011) USP22 Acts as an Oncogene by the Activation of BMI-1-Mediated INK4a/ARF Pathway and Akt Pathway. Cell Biochem Biophys 62: 229-35.
14. Xu H, Liu YL, Yang YM, Dong XS, (2012) Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth. Int J Colorectal Dis 27: 21-30.
15. Jiang J, Thyagarajan-Sahu A, Krchňák V, Jedinak A, Sandusky GE, et al. (2012) NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo. PLoS One 7: e34283.
16. Muir C, Weiland L, (1995) Upper aerodigestive tract cancers. Cancer 75: 147-153.
17. Miller CS, Henry RG, Rayens MK, (2003) Disparities in risk of and survival from oropharyngeal squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95: 570-575.
18. Wolff D, Hassfeld S, Hofele C, (2004) Influence of marginal and segmental mandibular resection on the survival rate in patients with squamous cell carcinoma of the inferior parts of the oral cavity. J Craniomaxillofac Surg 32: 318-323.
19. Glinsky GV, (2008) "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 26: 2846-2853.
20. Atanassov BS, Dent SY, (2011) USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep 12: 924-930.
21. Chipumuro E, Henriksen MA, (2012) The ubiquitin hydrolase USP22 contributes to 3′-end processing of JAK-STAT-inducible genes. FASEB J 26: 842-54.
22. Baker SP, Grant PA, (2007) The SAGA continues: expanding the cellular role of a transcriptional coactivator complex. Oncogene 26: 5329-5340.
23. Henry KW, Wyce A, Lo WS, Duggan LJ, Emre NC, et al. (2003) Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev 17: 2648-2663.
24. Daniel JA, Grant PA, (2007) Multi-tasking on chromatin with the SAGA coactivator complexes. Mutat Res 618: 135-148.